Foley Hoag LLP represented biotechnology ecosystem company Alloy Therapeutics Inc. ("Alloy") in a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") for the development of Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).
Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. The platform technology offers potential for "off-the-shelf" cell therapies with enhanced potency and significantly lower manufacturing costs compared to autologous cell therapy approaches. The collaboration will leverage Alloy's business model to further advance the platforms while enabling broader access to biotech and pharma partners to develop therapies for cancers including solid tumors.
Foley Hoag attorneys Sarah Cooleybeck, Mark Potash, Patrick Connolly and Ivanna Bihun represented Alloy Therapeutics in the transaction, with assistance from Amy Baker Mandragouras, Sarah Kelley and Kevin Lin.
Read more about the transaction here.